The NICE threshold will rise to \u00a325,000 to \u00a335,000 for every quality adjusted life year.<\/p>\n
In return for the changes, the White House will grant an exemption for U.K.-made pharmaceuticals, ingredients and medical technology from U.S. tariffs for the remainder of President Donald Trump\u2019s term.\u00a0<\/p>\n
U.K. Science Secretary Liz Kendall said the deal \u201cwill ensure UK patients get the cutting-edge medicines they need sooner, and our world-leading UK firms keep developing the treatments that can change lives.\u201d<\/p>\n
U.S. Commerce Secretary Howard Lutnick claimed the deal as a \u201cmajor win\u201d for American workers, adding: \u201cWe are strengthening supply chains, creating high-quality jobs, and reinforcing America as the world\u2019s premier hub for life-sciences investment.\u201d<\/p>\n
The breakthrough comes after months of back-and-forth between both sides, with the sector not covered in the Economic Prosperity Deal and Washington demanding a \u201cpreferential environment\u201d to lift the threat of steep import duties. The administration had threatened to impose up to 100 percent tariffs on drugs.\u00a0<\/p>\n
In July, the President issued a letter to 17 drugmakers, demanding they offer their drugs to Medicaid at most-favored-nation prices, prices tied to lower prices abroad, and shift manufacturing to U.S. soil.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"The NICE threshold will rise to \u00a325,000 to \u00a335,000 for every quality adjusted life year. In return for…\n","protected":false},"author":2,"featured_media":210192,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[275],"tags":[1820,3071,356,37807,18,440,135,475,474,19,31763,4286,17,15893,3283,2554,172,1255,393],"class_list":{"0":"post-210191","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-benchmarks","9":"tag-department","10":"tag-donald-trump","11":"tag-dumping-duties","12":"tag-eire","13":"tag-environment","14":"tag-health","15":"tag-health-care","16":"tag-healthcare","17":"tag-ie","18":"tag-imports","19":"tag-industry","20":"tag-ireland","21":"tag-negotiations","22":"tag-patients","23":"tag-pharma","24":"tag-research","25":"tag-tariffs","26":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/115646154899609391","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/210191","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=210191"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/210191\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/210192"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=210191"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=210191"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=210191"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}